China National Accord Medicines Corp Ltd (200028) — Capital Reinvestment Ratio
China National Accord Medicines Corp Ltd (200028) has a Capital Reinvestment Ratio of 0.03x as of June 2025, meaning it reinvests 0% of its operating cash flow (HK$1.83 Billion) in capital expenditures (HK$50.09 Million). See 200028 equity financing ratio to measure how much of total assets are equity-financed.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
China National Accord Medicines Corp Ltd Capital Reinvestment Ratio (1998–2025)
This chart tracks China National Accord Medicines Corp Ltd's Capital Reinvestment Ratio across 27 annual periods. Check cash flow reinvestment rate of China National Accord Medicines Corp Ltd to assess the company's total reinvestment commitment from operating cash flow.
Annual Capital Reinvestment Ratio for China National Accord Medicines Corp Ltd (1998–2025)
Year-by-year Capital Reinvestment Ratio for China National Accord Medicines Corp Ltd from 1998 to 2025. For live market cap and broader valuation context, see China National Accord Medicines Corp Ltd (200028) market capitalisation.
| Year | Reinvestment Ratio | Operating CF (HKD) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 0.13x | HK$1.64 Billion | HK$217.35 Million | ▲ +53.5% |
| 2024 | 0.09x | HK$3.27 Billion | HK$282.70 Million | ▼ -21.2% |
| 2023 | 0.11x | HK$2.94 Billion | HK$322.21 Million | ▼ -12.8% |
| 2022 | 0.13x | HK$2.56 Billion | HK$322.19 Million | ▼ -43.8% |
| 2021 | 0.22x | HK$1.66 Billion | HK$370.43 Million | ▲ +14.5% |
| 2020 | 0.20x | HK$1.50 Billion | HK$293.83 Million | ▲ +59.5% |
| 2019 | 0.12x | HK$2.00 Billion | HK$245.17 Million | ▼ -36.6% |
| 2018 | 0.19x | HK$1.32 Billion | HK$255.48 Million | ▲ +21.5% |
| 2017 | 0.16x | HK$1.29 Billion | HK$204.35 Million | ▼ -11.9% |
| 2016 | 0.18x | HK$1.47 Billion | HK$265.89 Million | ▼ -0.6% |
| 2015 | 0.18x | HK$1.05 Billion | HK$190.36 Million | ▼ -43.9% |
| 2013 | 0.32x | HK$465.03 Million | HK$150.50 Million | ▼ -45.8% |
| 2012 | 0.60x | HK$323.96 Million | HK$193.57 Million | ▼ -31.7% |
| 2011 | 0.88x | HK$227.32 Million | HK$198.97 Million | ▲ +110.6% |
| 2010 | 0.42x | HK$428.16 Million | HK$177.99 Million | ▲ +9.4% |
| 2009 | 0.38x | HK$270.85 Million | HK$102.94 Million | ▲ +10.3% |
| 2008 | 0.34x | HK$246.58 Million | HK$84.98 Million | ▼ -57.7% |
| 2007 | 0.81x | HK$87.70 Million | HK$71.41 Million | ▲ +25.2% |
| 2006 | 0.65x | HK$181.73 Million | HK$118.22 Million | ▲ +90.5% |
| 2005 | 0.34x | HK$148.28 Million | HK$50.62 Million | ▲ +213.6% |
| 2004 | 0.11x | HK$130.30 Million | HK$14.18 Million | ▼ -82.1% |
| 2003 | 0.61x | HK$81.22 Million | HK$49.36 Million | ▼ -35.0% |
| 2002 | 0.94x | HK$28.76 Million | HK$26.90 Million | ▲ +85.3% |
| 2001 | 0.50x | HK$71.16 Million | HK$35.91 Million | ▼ -79.5% |
| 2000 | 2.47x | HK$8.52 Million | HK$21.01 Million | ▲ +104.6% |
| 1999 | 1.21x | HK$22.84 Million | HK$27.54 Million | ▼ -39.5% |
| 1998 | 1.99x | HK$5.21 Million | HK$10.38 Million | — |